In a recent report, analysts at JMP Securities discussed five biotech names that are on their radar. Here’s a breakdown of what they had to say.
BIND Therapeutics Inc (NASDAQ:
BIND will be presenting three posters on its Accurin technology at the American Association of Cancer Research (AACR) meeting in Philadelphia in April.
Although the Accurin data the company will be showcasing is early-stage, analysts believe it demonstrates the potential of the technology.
JMP rates BIND Market Perform and has a $25 target for the stock.
Related Link: Is Intercept The Next Biotech To Break Out?
Cerulean Pharma Inc (NASDAQ:
The company’s Q4 results demonstrated impressive Phase Ib/II trial results for refractory renal cell carcinoma treatment.
JMP rates Cerulean Market Outperform and has a $16 target for the stock.
Flamel Technologies S.A. (ADR) (NASDAQ:
Flamel recently reaffirmed guidance and expects to be cash flow positive in 2015. Analysts are looking to the company’s pipeline for catalysts to drive the stock higher.
JMP rates Flamel Market Outperform and has a $25 target for the stock.
Karyopharm Therapeutics Inc (NASDAQ:
Abstracts that the company has submitted for the AACR meeting include 13 posters on selinexor mechanisms related to both solid and liquid tumors and five posters related to PAK4 allosteric modulators and anti-proliferative mechanisms. Analysts are encouraged by the preclinical advances that the company is making on numerous fronts.
JMP rates Karyopharm Market Outperform and has a $58 price target for the stock.
Teleflex Incorporated (NYSE:
Recent meetings with Teleflex management gave JMP analysts the impression that the company is “only approaching the middle innings” of its transformation. Analysts see fundamental improvements over the next five years, similar to the improvements the company has made in the last five years.
JMP rates Teleflex Market Outperform and has a $133 target for the stock.
Latest Ratings for BIND
View More Analyst Ratings for BIND
View the Latest Analyst Ratings
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investment & Company Information